Drugmakers look to HDL-raising pills as next big seller

11/30/2005 | Forbes

Large pharmaceutical companies, followed closely by smaller competitors, are racing to get onto the market drugs that raise high-density lipoprotein cholesterol levels. Pfizer is betting the $800 million it invested in developing torcetrapib will lead to $1 billion in sales during its first year on the market, but Merck, Roche Holding, Novartis and Kos Pharmaceuticals are close behind.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Medicare
UPMC Health Plan
Pittsburgh, PA
Actuary
Meridian Health Plan
Detroit, MI
National Affairs Analyst
Verisk Analytics
Jersey City, NJ
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC